{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:03:14Z","timestamp":1792598594227,"version":"4.5.0"},"reference-count":26,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2009,10,20]],"date-time":"2009-10-20T00:00:00Z","timestamp":1255996800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0007520","type":"journal-article","created":{"date-parts":[[2009,10,19]],"date-time":"2009-10-19T21:12:27Z","timestamp":1255986747000},"page":"e7520","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":60,"title":["Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10)"],"prefix":"10.1371","volume":"4","author":[{"given":"Tong","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye-Hong","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit K.","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hopper-Borge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyong","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2009,10,20]]},"reference":[{"key":"ref1","first-page":"71","article-title":"Cancer statistics.","volume":"58","author":"A Jemal","year":"2008","journal-title":"CA Cancer J Clin"},{"key":"ref2","first-page":"93","article-title":"Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: Evaluation of current strategies.","volume":"1(2)","author":"CP Wu","year":"2008","journal-title":"Curr Mol Pharmacol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.cad.0000127665.74096.93","article-title":"DNA repair pathways in drug resistance in melanoma.","volume":"15(5)","author":"PA Bradbury","year":"2004","journal-title":"Anticancer Drugs"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1152\/physrev.00035.2005","article-title":"Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins.","volume":"86","author":"RG Deeley","year":"2006","journal-title":"Physiol Rev"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1042\/bj20020957","article-title":"Structure and function of efflux pumps that confer resistance to drugs.","volume":"376(Pt 2)","author":"MI Borges-Walmsley","year":"2003","journal-title":"Biochem J"},{"key":"ref6","first-page":"393","article-title":"Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines.","volume":"30(2)","author":"H Naramoto","year":"2007","journal-title":"Int J Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1158\/0008-5472.CAN-03-3111","article-title":"Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel.","volume":"64","author":"E Hopper-Borge","year":"2004","journal-title":"Cancer Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1158\/0008-5472.CAN-08-1420","article-title":"Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epithilone B.","volume":"69(1)","author":"E Hopper-Borge","year":"2009","journal-title":"Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.bcp.2008.12.005","article-title":"Cepharanthine is a potent reversal agent for MRP7 (ABCC10)-mediated multidrug resistance.","volume":"77","author":"Y Zhou","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"11012","DOI":"10.1158\/0008-5472.CAN-07-2686","article-title":"Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.","volume":"67(22)","author":"Z Shi","year":"2007","journal-title":"Cancer Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-08-0499","article-title":"Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.","volume":"68(19)","author":"C Dai","year":"2008","journal-title":"Cancer Res"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bcp.2009.04.002","article-title":"Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1\/Pgp and ABCG2\/BCRP\/MXP transporters.","volume":"78(2)","author":"AK Tiwari","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.","volume":"21(14)","author":"J Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors.","volume":"279","author":"S Hirota","year":"1998","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"NP Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1182\/blood-2006-02-003145","article-title":"Functional ABCG2 is overexpressed on primary CML CD34<sup>+<\/sup> cells and is inhibited by imatinib mesylate.","volume":"108(4)","author":"NE Jordanides","year":"2006","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.","volume":"66(1)","author":"MM Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.","volume":"14(12)","author":"DK Hiwase","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.2174\/092986708786848578","article-title":"Targeted drugs in chronic myeloid leukemia.","volume":"15(29)","author":"J Gora-Tybor","year":"2008","journal-title":"Curr Med Chem"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/BF01534700","article-title":"Isolation and genetic characterization of human KB cell lines resistant to multiple drugs.","volume":"11(2)","author":"S Akiyama","year":"1985","journal-title":"Somat Cell Mol Genet"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0026-895X(24)13480-3","article-title":"Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P.","volume":"51(3)","author":"T Sumizawa","year":"1997","journal-title":"Mol Pharmacol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.","volume":"72","author":"MM Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumor stem cells and drug resistance.","volume":"5(4)","author":"M Dean","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1124\/pr.58.2.7","article-title":"The ATP-bind cassette transporters and their implications in drug disposition: a special look at the heart.","volume":"58(2)","author":"L Couture","year":"2006","journal-title":"Pharmacol Rev"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.","volume":"354(24)","author":"H Kantarjian","year":"2006","journal-title":"New Eng J Med"},{"key":"ref26","article-title":"Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.","author":"C Tanaka","journal-title":"Clin Pharmacol Ther"}],"updated-by":[{"DOI":"10.1371\/annotation\/e57b4610-9029-48db-9d57-5cc0fa35b8ac","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2009,11,12]],"date-time":"2009-11-12T00:00:00Z","timestamp":1257984000000}}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0007520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T20:57:02Z","timestamp":1739393822000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0007520"}},"subtitle":[],"editor":[{"given":"Debbie","family":"Fox","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,10,20]]},"references-count":26,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2009,10,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0007520","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,10,20]]}}}